- Home
- LUNG vs VTVT Comparison
LUNG vs VTVT Comparison
Compare LUNG & VTVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LUNG
- VTVT
- Stock Information
- Founded
- LUNG 1995
- VTVT 2015
- Country
- LUNG United States
- VTVT United States
- Employees
- LUNG 291
- VTVT N/A
- Industry
- LUNG Industrial Specialties
- VTVT Biotechnology: Pharmaceutical Preparations
- Sector
- LUNG Health Care
- VTVT Health Care
- Exchange
- LUNG Nasdaq
- VTVT Nasdaq
- Market Cap
- LUNG 63.6M
- VTVT 54.4M
- IPO Year
- LUNG 2020
- VTVT 2015
- Fundamental
- Price
- LUNG $1.98
- VTVT $20.89
- Analyst Decision
- LUNG Buy
- VTVT Strong Buy
- Analyst Count
- LUNG 7
- VTVT 2
- Target Price
- LUNG $7.66
- VTVT $35.50
- AVG Volume (30 Days)
- LUNG 827.7K
- VTVT 3.9K
- Earning Date
- LUNG 10-29-2025
- VTVT 11-11-2025
- Dividend Yield
- LUNG N/A
- VTVT N/A
- EPS Growth
- LUNG N/A
- VTVT N/A
- EPS
- LUNG N/A
- VTVT N/A
- Revenue
- LUNG $90,549,000.00
- VTVT $17,000.00
- Revenue This Year
- LUNG $10.30
- VTVT N/A
- Revenue Next Year
- LUNG $14.72
- VTVT N/A
- P/E Ratio
- LUNG N/A
- VTVT N/A
- Revenue Growth
- LUNG 18.24
- VTVT N/A
- 52 Week Low
- LUNG $1.47
- VTVT $12.62
- 52 Week High
- LUNG $9.37
- VTVT $26.99
- Technical
- Relative Strength Index (RSI)
- LUNG 62.99
- VTVT 48.86
- Support Level
- LUNG $1.56
- VTVT $20.19
- Resistance Level
- LUNG $1.67
- VTVT $21.20
- Average True Range (ATR)
- LUNG 0.15
- VTVT 0.97
- MACD
- LUNG 0.03
- VTVT -0.30
- Stochastic Oscillator
- LUNG 33.58
- VTVT 33.54
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.
About VTVT vTv Therapeutics Inc.
vTv Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin, being investigated for the treatment of type 1 diabetes (T1D). Its product pipeline includes TTP399, TTP273, HPP737, HPP593, Azeliragon, HPP971, HPP3033, and TTP-RA.